Against the background of a global public health crisis and in the immediate aftermath of a game-changing US Presidential election, the FT Global Pharmaceutical and Biotechnology Conference agenda will provide an opportune moment to analyse the implications of these momentous events for the industry’s on-going transformation.

Oncology and beyond: how sustainable is the industry's current concentration on oncology and rare diseases?

Coronavirus: a 21st century case study of pharma and health

The changing power structure of the industry - how is the pharma innovation model evolving?

The million dollar question - how do we pay for cures?

Are manufacturing and supply chains the new competitive edge for pharma?

Head of Market Access, CSL Behring
“Broad themes covered from a wide range of stakeholders.”